Mitiperstat Fails to Reduce COPD Exacerbations
A phase 2a trial found the oral myeloperoxidase inhibitor did not improve outcomes for adults with moderate-to-severe COPD.
Updated on Nov. 15, 2026 in Asthma

The randomised, placebo-controlled CRESCENDO trial tested mitiperstat as an add-on to existing inhaled treatment in 381 adults with COPD. Mitiperstat did not improve exacerbation outcomes, lung function, or respiratory symptoms compared with placebo.
Why it matters
The results indicate that inhibiting myeloperoxidase, an enzyme linked to neutrophils, does not offer an additional treatment benefit for COPD patients whose disease remains difficult to control on standard therapy. Pneumonia also occurred more often in the mitiperstat group, a finding that will shape how the compound is evaluated going forward.
The phase 2a trial randomised 381 adults aged 40-80 with moderate-to-severe COPD, with COPDCompEx events in 66.1% of the mitiperstat group versus 65.1% of placebo (hazard ratio 1.07, 90% CI 0.87-1.32). Longer-term safety and effects beyond the 24-week dosing period remain unknown.
The players
European Respiratory Journal
The European Respiratory Journal is a peer-reviewed medical journal published by the European Respiratory Society, widely read by respiratory researchers and clinicians.
The details
Participants took mitiperstat 5 mg or placebo once daily for up to 24 weeks while continuing their established dual or triple inhaled therapy. The study combined remote and in-person assessments with home monitoring, and its primary outcome was time to a first COPDCompEx event.
Timeline
Participants received daily dosing for up to 24 weeks in the CRESCENDO trial.
The trial results were published in the European Respiratory Journal in 2026.
Health Landscape
The CRESCENDO result is a negative phase 2a test of myeloperoxidase inhibition, a neutrophil-linked pathway that researchers have pursued as an add-on to inhaled COPD therapy. It shows that the pathway's promise in lung disease has not yet translated into exacerbation benefit at this stage of development.
For COPD patients, this result means mitiperstat is not an available add-on option on the basis of current evidence, so existing inhaled therapy remains the standard approach. Patients should continue their prescribed treatment and discuss any new symptoms or changes with their clinician.
The takeaway
The negative CRESCENDO result shows that promising biological targets must still prove clinical benefit in patients, and the pneumonia signal reinforces the need for careful safety monitoring. Patients with COPD should keep following their current treatment plan while larger studies determine whether this pathway can help.
Further reading
For background on respiratory conditions that share airway inflammation with COPD, see Asthma.
Source note: This article includes information reported by European Medical Journal.



